ʻO Vericiguat kahipyrazolopyridineo ia5-fluoro-1H-pyrazolo[3,4-b]pyridinekahi i hoʻololi ʻia ai ka amino hydrogen ma ke kūlana 1 e kahi hui 2-fluorobenzyl a me kahydrogenma ke kūlana 3 ua hoʻololi ʻia e kahi hui 4,6-diamino-5-[(methoxycarbonyl)amino]pyrimidin-2-yl.He mea hoʻoheheʻeguanylatecyclase stimulator i hoʻohana ʻia no ka mālama ʻana i ka puʻuwai puʻuwai mau.He kuleana kona ma ke ʻano he mea hoʻoheheʻeguanylatecyclase activator, he lāʻau vasodilator a he lāʻau antihypertensive.Heaminopyrimidine, apyrazolopyridine, he ester carbamate a me ka hui organofluorine.

Ke hoʻokolokolo ʻia nei ʻo Vericiguat i ka hoʻokolohua lapaʻau NCT02861534 (A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)).

ʻO Vericiguat kahi mea hoʻoheheʻeGuanylateMea hoʻoulu ʻo Cyclase.ʻO ka hana o ka vericiguat e like me aGuanylateMea hoʻoulu ʻo Cyclase.

He lāʻau lapaʻau ʻo Vericiguat i hoʻohana ʻia no ka mālama ʻana a me ka mālama ʻana i ka pau ʻole o ka naʻau me ka haʻihaʻi ejection hōʻemi (HFrEF).He mea maikaʻi ia no ka hōʻino ʻole ʻana o ka naʻau, ka puʻuwai decompensated hou.ʻAʻole hoʻolōʻihi ʻo Vericiguat i ke ola akā pale i ka hoʻokipa hou.Hōʻike kēia haʻawina i nā hōʻailona, ​​​​mekini o ka hana, ka nui, a me ke ʻano o ka hoʻokele ʻana e ka hui interprofessional, nā hopena ʻino, contraindications, a me kekahi mau hoʻāʻo e kākoʻo i nā hōʻike o ka pono o ka lāʻau i ka HFrEF.